Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, et al.

J Virol. 1994 Mar;68(3):1660-6.

2.

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates.

Nájera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, Nájera R, López-Galíndez C.

AIDS Res Hum Retroviruses. 1994 Nov;10(11):1479-88.

PMID:
7534096
5.

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.

Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC.

J Virol. 1996 Feb;70(2):1086-90.

6.

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.

Nature. 1993 Feb 18;361(6413):650-4. Erratum in: Nature. 1993 Aug 19;364(6439):679.

PMID:
7679778
7.

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.

Larder BA, Kellam P, Kemp SD.

Nature. 1993 Sep 30;365(6445):451-3.

PMID:
7692302
8.

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor.

Staszewski S, Massari FE, Kober A, Göhler R, Durr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, et al.

J Infect Dis. 1995 May;171(5):1159-65.

PMID:
7538547
9.
12.

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.

Larder BA, Kemp SD, Harrigan PR.

Science. 1995 Aug 4;269(5224):696-9.

PMID:
7542804
14.

Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.

Buckheit RW Jr, Fliakas-Boltz V, Yeagy-Bargo S, Weislow O, Mayers DL, Boyer PL, Hughes SH, Pan BC, Chu SH, Bader JP.

Virology. 1995 Jun 20;210(1):186-93.

15.

Zidovudine and lamivudine: results of phase III studies.

Staszewski S.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S57.

PMID:
8595510
16.

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.

Antivir Chem Chemother. 2000 Jul;11(4):291-301.

PMID:
10950391
17.
18.

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.

Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Riess G.

Virology. 1994 May 1;200(2):696-701.

PMID:
7513921
19.

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Richman D, Shih CK, Lowy I, Rose J, Prodanovich P, Goff S, Griffin J.

Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11241-5.

20.

Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.

de Jong MD, Loewenthal M, Boucher CA, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R, et al.

J Infect Dis. 1994 Jun;169(6):1346-50.

PMID:
8195615
Items per page

Supplemental Content

Write to the Help Desk